

ABC OF HYPERTENSION

Fifth Edition

Edited by

D GARETH BEEVERS

*Professor of medicine, University Department of Medicine,
City Hospital, Birmingham*

GREGORY Y H LIP

*Professor of cardiovascular medicine, University Department of Medicine,
City Hospital, Birmingham*

and

EOIN O'BRIEN

*Professor of molecular pharmacology, Conway Institute of Biomolecular and
Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland*

BMJ
Books



Blackwell
Publishing

منتدى افريقيا سات

www.afriqa-sat.com



المهندس : عبدالعزيز الضاوي

للمراسلة على الفيس بوك

الضاوي سات

www.facebook.com/aldawi.sat

© 1981, 1987, 1995, 2001 BMJ Books
© 2007 Blackwell Publishing Ltd
BMJ Books is an imprint of the BMJ Publishing Group Limited, used under licence

Blackwell Publishing Inc., 350 Main Street, Malden, Massachusetts 02148-5020, USA
Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK
Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia

The right of the Author to be identified as the Author of the Work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior written permission of the publisher.

First published 1981
Second edition 1987
Third edition 1995
Fourth edition 2001
Fifth edition 2007

1 2007

Library of Congress Cataloging-in-Publication Data

Beevers, D. G. (D. Gareth)

ABC of hypertension / D. Gareth Beevers, Gregory Y. H. Lip, and Eoin O'Brien.—5th ed.

p. ; cm.

Includes bibliographical references and index.

ISBN: 978-1-4051-3061-5 (alk. paper)

1. Hypertension. I. Lip, Gregory Y. H. II. O'Brien, Eoin. III. Title.

[DNLM: 1. Hypertension—diagnosis. 2. Blood Pressure Determination—methods.

3. Hypertension—therapy. WG 340 B415a 2007]

RC685. H8B34 2007

616.1'32—dc22

2006027936

ISBN: 978-1-4051-3061-5

A catalogue record for this title is available from the British Library

Cover image is courtesy of TEK Image/Science Photo Library

Set in 9/11 pts New Baskerville by Newgen Imaging Systems (P) Ltd, Chennai, India

Printed and bound in Singapore by Markono Print Media Pte Ltd

Commissioning Editor: Eleanor Lines

Development Editors: Sally Carter, Nick Morgan

Editorial Assistant: Victoria Pittman

Production Controller: Rachel Edwards

For further information on Blackwell Publishing, visit our website:

<http://www.blackwellpublishing.com>

The publisher's policy is to use permanent paper from mills that operate a sustainable forestry policy, and which has been manufactured from pulp processed using acid-free and elementary chlorine-free practices. Furthermore, the publisher ensures that the text paper and cover board used have met acceptable environmental accreditation standards.

Blackwell Publishing makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check that any product mentioned in this publication is used in accordance with the prescribing information prepared by the manufacturers. The author and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this book.

Contents

<i>Preface</i>	iv
1 Prevalence and causes	1
<i>G Y H Lip, D G Beevers</i>	
2 Hypertension and vascular risk	7
<i>G Y H Lip, D G Beevers</i>	
3 Pathophysiology of hypertension	12
<i>G Y H Lip, D G Beevers</i>	
4 Measurement of blood pressure	
Part I: Apects of measurement of blood pressure common to technique and patient	17
Part II: Conventional sphygmomanometry	22
Part III: Ambulatory blood pressure measurement	26
Part IV: Self-measurement of blood pressure	30
<i>Eoin O'Brien</i>	
5 Screening and management in primary care	33
<i>G Y H Lip, D G Beevers</i>	
6 Clinical assessment of patients with hypertension	37
<i>G Y H Lip, D G Beevers</i>	
7 Investigation in patients with hypertension	40
<i>G Y H Lip, D G Beevers</i>	
8 Non-pharmacological treatment of hypertension	44
<i>G Y H Lip, D G Beevers</i>	
9 Pharmacological treatment of hypertension	47
<i>G Y H Lip, D G Beevers</i>	
10 Hypertension in patients with cardiovascular disease	56
<i>G Y H Lip, D G Beevers</i>	
11 Special groups—diabetes, renal disease, and connective tissue disease	61
<i>G Y H Lip, D G Beevers</i>	
12 Ethnicity and age	65
<i>G Y H Lip, D G Beevers</i>	
13 Pregnancy and oral contraceptives	68
<i>G Y H Lip, D G Beevers</i>	
<i>Appendix</i>	74
<i>Index</i>	77

Preface

The first edition of the *ABC of Hypertension*, published in 1981, rose out of a series of review articles published in the *British Medical Journal* under the titles of *ABC of blood pressure measurement* and *ABC of blood pressure reduction*. Since that time there have been a great many advances in our understanding of clinical aspects of hypertension that have necessitated regular updating. In particular there have been major improvements in the measurement of blood pressure with increasing awareness of the relative importance of 24 hour ambulatory blood pressure monitoring versus casual office blood pressure readings. In addition, the focus of the management of hypertensive patients has moved to encompass a measure of total cardiovascular risk rather than just the blood pressure. This has been helped by the ready availability of simple risk charts, particularly those published by the British Hypertension Society and the joint British Societies. Along with this there has been an increasing awareness that the height for systolic blood pressure is a better predictor of cardiovascular risk than the diastolic blood pressure and that isolated systolic hypertension, with its high risk, is well worth treating. Even today, however, many clinicians who were originally taught that the diastolic pressure was more important than the systolic are finding this radical change in emphasis to be somewhat startling.

The first edition of the *ABC of Hypertension* was published before the era of angiotensin converting enzyme inhibitors. There is no doubt that these agents, together with the more recently synthesised angiotensin receptor blockers are by far the most tolerable antihypertensive drugs. They have transformed the treatment of diabetic hypertensives and hypertensives with concomitant heart disease or nephropathy. Since the publication of the fourth edition of the *ABC of Hypertension*, we have seen publication of the Losartan Intervention For Endpoint (LIFE) study and the Anglo Scandinavian Cardiac Outcomes Trial (ASCOT). In both of these trials the drugs that block the renin-angiotensin system were found to be superior to previous standard regimes of atenolol with or without a thiazide diuretic. These two trials have heralded the end of the supremacy of β blockers in the treatment of uncomplicated hypertension. Again, this will be a radical turnaround for those clinicians who have put their faith in β blockers for uncomplicated essential hypertension in the hope that they might be better at preventing first coronary events than other agents.

Thus, since 1980 we have become better at assessing our patients' blood pressure, better at assessing their cardiovascular risk, and we have more effective and more tolerable antihypertensive agents. In previous years a clinician, when faced with a patient where the value of treatment was open to question, might have taken the view "when in doubt, don't treat." Nowadays the same clinician, when faced with a similar patient, is more likely to say "when in doubt, treat." This view, together with the arrival of the statins, means that lives are being saved and people are living longer.

Publication of the LIFE trial and ASCOT brings us to a sort of plateau in the topic of clinical hypertension research. Although there is no doubt that there are many advances to be looked forward to in the topic of the basic cardiovascular sciences, it is unlikely that we will have much more information on clinical care for a few years. Perhaps the biggest problem now is to improve the quality and efficiency of the delivery of the various validated treatments to individual patients. We are acutely aware that this healthcare delivery is mainly the responsibility of the primary healthcare team based in general practice. We hope that this fifth edition of the *ABC of Hypertension* provides sufficient evidence based material to guide clinicians in the correct manner of investigating and managing hypertensive patients while providing pragmatic guidance on good clinical practice that can be applied in any healthcare delivery system. Things have changed so much over the last 25 years that the *ABC of Hypertension* remains necessary to help clinicians manage the most common chronic medical condition world-wide. We hope therefore that this edition will provide useful guidance for clinicians in developing as well as developed countries.

DG Beevers
GYH Lip
E O'Brien

1 Prevalence and causes

G YH Lip, D G Beevers

In the population, blood pressure is a continuous, normally distributed variable. No separate subgroups of people with and without hypertension exist. A consistent continuous gradient exists between usual levels of blood pressure and the risk of coronary heart disease and stroke, and this gradient continues down to blood pressures that are well below the average for the population. This means that much of the burden of renal disease and cardiovascular disease related to blood pressure can be attributed to blood pressures within the so called “normotensive” or average range for Western populations.

The main concern for doctors is what level of blood pressure needs drug treatment. The pragmatic definition of hypertension is the level of blood pressure at which treatment is worthwhile. This level varies from patient to patient and balances the risks of untreated hypertension in different types of patients and the known benefits of reducing blood pressure, while taking into account the disadvantages of taking drugs and the likelihood of side effects.

“In an operational sense, hypertension should be defined in terms of a blood pressure level above which investigation and treatment do more good than harm” Grimley Evans J, Rose G. *Br Med Bull* 1971;27:37–42


Systolic blood pressure has a strong tendency to increase with advancing age, so the prevalence of hypertension (and its complications) also increases with age. Hypertension thus is as much a disorder of populations as of individual people. Globally, high blood pressure accounts for more deaths than many common conditions and is a major burden of disease.

As hypertension is the most important risk factor for cardiovascular disease, achievement of a universal target systolic blood pressure of 140 mm Hg should produce a reduction of 28–44% in the incidence of stroke and 20–35% of coronary heart disease. This could prevent about 21 400 deaths from stroke and 41 400 deaths from coronary heart disease in the United Kingdom each year. It would also mean about 42 800 fewer fatal and non-fatal strokes and 82 800 fewer coronary heart disease events per year in the United Kingdom alone. Globally, as hypertension is becoming more common, coronary heart disease and stroke correspondingly are becoming common, particularly in developing countries.


A recently published analysis of pooled data from different regions of the world estimated the overall prevalence and absolute burden of hypertension in 2000 and the global burden in 2025. Overall, 26.4% of the adult population in 2000 had hypertension and 29.2% were projected to have this condition by 2025. The estimated total number of adults with hypertension in 2000 was 972 million: 333 million in economically developed countries and 639 million in economically developing countries. The number of adults with hypertension in 2025 thus is predicted to increase by about 60% to a total of 156 billion.

The development of hypertension reflects a complex and dynamic interaction between genetic and environmental factors. In some primitive communities in which obesity is rare and salt intake is low, hypertension is virtually unknown, and blood pressure does not increase with advancing age.


Studies have investigated Japanese people migrating from Japan to the west coast of America. In Japan, high blood



Hypertension: a disease of quantity not quality



Birmingham Factory Screening Project (figure excludes data from 165 patients on drugs that lower blood pressure). Adapted from Lane D, et al. *J Human Hypertens* 2002;16:267–73



Worldwide causes of death. Adapted from Mackay J, Mensah GA, WHO 2004

ABC of hypertension

pressure is common and the incidence of stroke is high, but coronary heart disease is rare. When Japanese people moved across the Pacific Ocean, a reduction in the incidence of hypertension and stroke was seen, but the incidence of coronary heart disease increased. These studies strongly suggest that, although racial differences exist in the predisposition to hypertension, environmental factors still play a significant role. The United Kingdom also has a pronounced north–south gradient in blood pressure, with pressures higher in the north of the country. Studies that compare urban and rural populations in African populations also show clear differences in blood pressure between urban and rural societies with the same genetic composition.

Prevalence

The prevalence of hypertension in the general population depends on the arbitrary criteria used for its definition, as well as the population studied. In 2853 participants in the Birmingham Factory Screening Project, the odds ratios for being hypertensive after adjustment for age were 1.56 and 2.40 for African-Caribbean men and women, respectively, and 1.31 for South-Asian men compared with Europeans.

The Third National Health and Nutrition Examination Survey 1988–91 (NHANES III) showed that 24% of the adult population in the United States, which represents more than 43 million people, have hypertension (>140/90 mm Hg or current treatment for hypertension). The prevalence of hypertension varies from 4% in people aged 18–29 years to 65% in people older than 80 years. Prevalence is higher among men than women, and the prevalence in African-Americans is higher than in Caucasians and Mexican-Americans (32.4%, 23.3%, and 22.6%, respectively). Most cases of hypertension in young adults result from increases in diastolic blood pressure, whereas in elderly people, isolated increases in systolic blood pressure are more common and account for 60% of cases of hypertension in men and 70% in women. Hypertension generally affects ≤10% of the population up to the age of 34 years. By the age of 65, however, more than half of the population has hypertension.

Incidence

Unfortunately, few data are available on the incidence of new onset hypertension. The incidence of hypertension does increase sharply with age, with higher rates in men.

Follow up of people in the Framingham Heart Study after 30 years found that the two year incidence of new onset hypertension increases from 3.3% in men and 1.5% in women aged 30–39 years to 6.2% in men and 8.6% in women aged 70–79 years. People with “high normal” blood pressure at first examination were at greater risk of developing sustained hypertension over the ensuing years. Some authorities argue that high normal blood pressure should be reclassified as “prehypertensive.”


“High normal” blood pressure is one of the strongest predictors for the later development of hypertension. At the individual level, however, blood pressure in childhood is poorly predictive of later levels of blood pressure or the risk of hypertension.

Age


In western societies, blood pressure rises with increasing age, and people with high baseline blood pressures have a faster increase than those with normal or below average pressures. In rural non-Westernised societies, however, hypertension is rare, and the increase in pressure with age is much smaller. The level of blood pressure accurately predicts coronary heart disease and stroke at all ages, although in very elderly people, the

Prevalence of hypertension (>160/95 mm Hg or treated) in the Birmingham Factory Screening Project


Population	Men (%)	Women (%)
African-Caribbean	30.8	34.4
European	19.4	12.9
South Asian	16.0	–



Hypertension subtypes from the NHANES III study (DBP = diastolic blood pressure, SBP = systolic blood pressure). Adapted from Franklin SS, et al. *Hypertension* 2001;37:869–74



Prevalence of hypertension in US citizens aged ≥35 years by age and sex in the NHANES III study (1988–94). Those classified as having hypertension had a systolic blood pressure ≥140 mm Hg or a diastolic blood pressure of ≥90 mm Hg, were taking antihypertensive drugs. Adapted from Wolz M, et al. *Am J Hypertens* 2000;13:104–4



Patients progressing to develop new hypertension in the Framingham Heart Study. Adapted from Vasan RS, et al. *Lancet* 2001;358:1682–6

relation is less clear. This may be because many people with increased blood pressures have died and those with lower pressure may have subclinical or overt heart disease that causes their blood pressure to decrease.

Ethnic origin

People of African origin have been studied well in North America, but whether these data can be fully applicable to the African-Caribbean populations in the United Kingdom or similar populations in Africa or the West Indies is uncertain. All studies of people of African origin from urban communities, however, show a higher prevalence than in Caucasian people. Yet hypertension is rare in black people who live in rural Africa. Whether any particular level of blood pressure carries a worse prognosis in people of African origin or whether survival is much the same as in people of European origin but with more strokes and fewer heart attacks is uncertain.

Even when correction is made for obesity, socioeconomic, and dietary factors, ethnic factors remain in the predisposition to hypertension. These differences are probably related to ethnic differences in salt sensitivity. There is little evidence to show that people of African origin in the United Kingdom and United States consume more salt than people of European origin. There is evidence that salt loading raises blood pressure more in people of African origin and that salt restriction is more beneficial. These differences in salt sensitivity may also be related to the finding that plasma levels of renin and angiotensin in African-American people are about half those in Americans of European origin. As discussed later, differences in renin may explain ethnic differences in responses to antihypertensive drugs.

Sex

Before the age of about 50 years, hypertension is less common in women than men. After this age, blood pressure in women gradually increases to about the same level as in men. Consequently, the complications of hypertension are less common in younger women. This protection may be related to beneficial effects of oestrogens or a harmful effect of androgens on vascular risk.

Increasing evidence shows that women with a past history of pre-eclampsia and pregnancy induced or gestational hypertension have an increased risk of hypertension and cardiovascular disease in later life. Such women should be considered to be at higher risk and need regular monitoring.

Causes of hypertension

In around 5% of people with hypertension, the high blood pressure is explained by underlying renal or adrenal diseases. In the remaining 95%, no clear cause can be identified. Such cases of hypertension are described as "essential" or "primary" hypertension. Essential hypertension is related to the interplay of genetic and environmental factors, but the precise role of these is uncertain.

Environmental and lifestyle causes of hypertension


Salt

Salt intake has a consistent and direct effect on blood pressure. As stated earlier, migration studies in African and Japanese people have shown changes in blood pressure when moving from one environmental background to another. The factor most likely to be involved is a change in salt intake.


Many potential mechanisms for how salt causes hypertension have been suggested. Evidence from observational

Blood pressure in populations of African origin in the United Kingdom: review of 14 adult cross sectional studies in 1978

Blood pressure	Men	Women
Systolic higher than Europeans	10 of 14	10 of 12
Diastolic higher than Europeans	11 of 14	10 of 12
Hypertension more common	8 of 10	8 of 9



Effect of salt loading in black and white normotensive people. Adapted from Luft FC, et al. *Circulation* 1979;59:643-50



Prevalence of secondary hypertension in the Health Survey for England 1998. Adapted from Primates P, et al. *Hypertension* 2001;38:827-32

Prevalence of secondary hypertension in three published surveys

Type of hypertension	Study		
	Rudnick, 1977	Sinclair, 1987	Anderson, 1994
Essential hypertension	94.0%	92.1%	89.5%
Renal disease	5.0%	5.6%	1.8%
Renal artery disease	0.2%	0.7%	3.3%
Cushing's syndrome	0.2%	0.1%	-
Oral contraceptives	0.2%	1.0%	-
Phaeochromocytoma	-	0.1%	0.3%
Coarctation	0.2%	-	-

How does salt cause hypertension?

- Increased circulating fluid volume
- Inappropriate sodium:renin ratio, with failure of renin to suppress increased intracellular sodium
- Waterlogged, swollen endothelial cells that reduce the interior diameter of arterioles
- Permissive rise in intracellular calcium, which leads to contraction of vascular smooth muscle

ABC of hypertension

epidemiological studies, animal models, and randomised controlled trials in patients with hypertension and normal blood pressure all point to a causal relation between salt and blood pressure. The potential clinical and public health impact of relatively modest salt restriction thus is substantial.

The Intersalt project, which involved more than 10 000 men and women aged 20–59 years in 52 different populations in 32 countries, quite clearly showed that the increase in blood pressure with advancing age in urban societies was related to the amount of salt in the diet. Positive associations between urinary excretion of sodium (a marker of salt intake) and blood pressure were observed within and between populations. In men and women of all ages, an increase in sodium intake of 100 mmol/day was estimated to be associated with an average increase in systolic blood pressure of up to 6 mm Hg. The association was larger for older people.

This finding was supported by a meta-analysis of the many individual population surveys of blood pressure in relation to salt intake. Law et al performed a meta-analysis of 78 trials of the effect of sodium intake on blood pressure and reported that a reduction in daily salt intake of about 3 g (attainable by moderate reductions in dietary intake of salt) in people aged 50–59 years should lower systolic blood pressure by an average of 5 mm Hg. An average reduction in blood pressure of this magnitude in the general population of most Western countries would reduce the incidence of stroke by 25% and the incidence of ischaemic heart disease by 15%.

A number of clinical trials also show reductions in blood pressure after restriction of salt intake (see chapter 8). In a recent study in the United Kingdom, a reduction in daily salt intake from 10 g to 5 g over one month in a group of men and women aged 60–78 years with hypertension resulted in an average fall in systolic blood pressure of 7 mm Hg.

The value of the restriction of salt intake in people without hypertension is more controversial. Data pooled from the limited studies available suggest that reduction of salt intake to about 6 g/day should reduce systolic blood pressure by about 2 mm Hg and diastolic pressure by 1 mm Hg. Although clinically unimportant, this reduction, if genuine and sustained, would be expected to bring about a 17% reduction in the prevalence of hypertension.


Potassium

The relation between intake of sodium, intake of potassium, and blood pressure is complex and has not been resolved completely. The effect of dietary intake of potassium on blood pressure is difficult to separate from that of salt.

The Intersalt project showed that high intake of potassium was associated with a lower prevalence of hypertension. Urinary sodium and potassium ratios in the United States showed marked differences between black and white people, despite little difference in their sodium intake or excretion. Dietary intake of potassium also has been related inversely to the risk of stroke. The antihypertensive effects of potassium chloride and other potassium salts are the same, which indicates that it is the potassium that matters. Most of the potassium in the diet is not in the form of potassium chloride but potassium citrate and potassium bicarbonate.

Calcium and magnesium

A weak inverse association exists between intake of calcium and blood pressure. Nonetheless, data from clinical trials of calcium supplementation on blood pressure are inconsistent, and the overall effect probably is minimal. A weak relation also exists between intake of magnesium and blood pressure, but the use of magnesium supplements has been disappointing.



Intersalt project. Adapted from INTERSALT cooperative research group. *BMJ* 1988;297:319–28

INTERSALT project: sodium excretion and systolic blood pressure in individual centres

Variable	Adjusted for	
	Age, sex	Age, sex, body mass index (kg/m ²), alcohol, and potassium
Centres with positive change	39	33
Centres with significantly positive change	15	8
Combined centre coefficient per mm Hg per 100 mmol of sodium	1.63*	1.00*
Combined centre coefficient corrected for reliability	3.54	2.17

*P < 0.001.

Adapted from INTERSALT cooperative research group. *BMJ* 1988;297:319–28

INTERSALT project: within centre coefficients for potassium in 24 hour urine sampling adjusted for age and sex

Variable	Blood pressure	
	Systolic	Diastolic
Positive coefficients:	24	29
Significant	0	2
Negative coefficients:	28	23
Significant	2	2
Centres	52	52

Adapted from INTERSALT cooperative research group. *BMJ* 1988;297:319–28

Weight

People who are obese or overweight tend to have higher blood pressures than thin people. Even after taking into account the confounding effects of obese arms and inappropriate cuff sizes on blood pressure measurement, a positive relation still exists between blood pressure and obesity—whether expressed as body mass index (weight (kg)/(height (m)²)), relative weight, skinfold thickness, or waist to hip ratio. An increase in body weight from childhood to young adulthood is a major predictor of adult hypertension.

This association is clearly related to a high energy diet, although other dietary factors may be implicated (for example, high intake of sodium). The risk is greater in patients with truncal obesity, which may be a marker for insulin resistance, activation of the sympathetic nervous system, or other pathophysiological mechanisms that link obesity and hypertension. The close association of obesity with diabetes mellitus, insulin resistance, and impaired glucose tolerance and high levels of plasma lipids also partly explains why obesity is such a powerful risk factor for cardiovascular disease.

In general, trials of weight reduction show changes in mean systolic blood pressure and diastolic blood pressure of about 5.2 mm Hg in patients with hypertension and 2.5 mm Hg in people with normal blood pressure. This translates roughly to a reduction in blood pressure of 1 mm Hg for each kilogram of weight loss.

Alcohol

Epidemiological studies have shown a positive relation between alcohol consumption and blood pressure, which is independent of age, obesity, cigarette smoking, social class, and sodium excretion. In the British Regional Heart Study, about 10% of cases of hypertension (blood pressure $\geq 160/95$ mm Hg) could be attributed to moderate or heavy drinking. Generally, the greater the alcohol consumption, the higher the blood pressure, although teetotalers seem to have slightly higher blood pressures than moderate drinkers.


The reversibility of hypertension related to alcohol has been shown in population surveys and alcohol loading and restriction studies. A reduction in weekly alcohol consumption is associated with clinically significant decreases in blood pressure, independent of weight loss, in people with normal blood pressure and those with hypertension. A reduction in intake of about three drinks per week was estimated to result in an average fall in supine systolic blood pressure of 3.1 mm Hg.

The mechanisms of the relation between alcohol and blood pressure are uncertain, but they are not explained by body mass index or salt intake. The effects of alcohol on blood pressure may include:


- A direct pressor effect of alcohol
- Sensitisation of resistance vessels to pressor substances
- Stimulation of the sympathetic nervous system (possibly as a result of fluctuating levels of alcohol in blood)
- Increased production of adrenocorticoid hormones.

Stress


Psychological or environmental stress may play a small part in the aetiology of hypertension, although studies frequently have been confounded by other environmental or lifestyle factors. Although research has focused on possible direct effects of psychosocial “stress” on blood pressure, “stressors” such as poverty, unemployment, and poor education are involved, as are other aspects of lifestyle that are linked to hypertension (including obesity, a diet high in salt, and physical inactivity).



Hypertension and body mass index (BMI) observed in the NHANES III study. Adapted from Thompson PD, et al. *Arch Intern Med* 1999;159:2177–83



Alcohol and hypertension. in a working population. Adapted from Arkwright P, et al. *Circulation* 1982;66:60–6



Stress, ethnicity, and hypertension in men. Stress was classified by residential area and crime rates. Adapted from Harburg E, et al. *J Chronic Dis* 1973;26:595–611